NCT01231542 - Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572

GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.

DRUG

Rifampin

Rifampin is approved by the FDA for the treatment of tuberculosis.

DRUG

Rifabutin

Rifabutin is approved by the FDA for the treatment of tuberculosis.

Trial Locations (1)

GSK Investigational Site, Baltimore